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Abstract
Background: Cervical cancer is a real public health problem in African countries. The relation between HPV and
cervical cancer is well established. However, it is known that the distribution of HPV genotypes differ geographically
and this may influence the effectiveness of the three available vaccines, which among other HPV genotypes targets
the genotypes 16 and 18 that cause about 70 % of cervical cancers cases. The objective of this study was to identify for
the first time the HPV genotypes distribution in cervical cancer specimens obtained from Gabonese women.
Methods: A total of 105 cervical samples including 93 formalin-fixed paraffin embedded tissues collected between
2007 and 2013 and 12 fresh biopsies collected in August 2013 were investigated. The presence of HPV DNA was
analyzed by nested PCR with primers MY09/11 and GP5+/6+ followed by sequencing for HPV genotyping.
Results: Amplification of the housekeeping gene (β-globin) with PCO4/GH20 primers was successful for 91.4 % (96/105)
of the cervical cancer samples and HPV DNA was detected in all the 96 samples. Five different HPV genotypes were
identified. HPV 16 [58.3 %; 95 % IC: 48.44–68.16] was the most common genotype followed by HPV 33 [25.0 %; 95 % IC:
16.34–33.66], HPV 18 [8.4 %; 95 % IC: 2.86–13.94], HPV 70 [7.3 %; 95 % IC: 2.1–12.5] and HPV 31 [1.1 %; 95 % IC: −0.986–3.
186]. HPV 16 was also the most prevalent in all histological malignant lesions. It was found in 56.6 % of squamous cervical
carcinoma and 69.2 % of adenocarcinoma. Concerning the HPV positive adenocarcinoma cases, HPV 18 was identified
in 7.7 % (1/13).
Conclusion: These findings show the predominance of HPV 16 in cervical cancer cases among Gabonese women.
However, HPV33 is more prevalent than HPV18. Our study suggests that HPV vaccines may be effective at reducing the
burden of cervical cancer in Gabon.
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Background
Infection with high risk oncogenic Human Papillomavirus
(HPV) plays a necessary role in the development of
cervical cancer, which is the third most frequent
gynecological malignancy in women worldwide [1]. It has
been estimated that about 529,800 new cases and 275,100
deaths occurs each year [1]. The burden of this disease is
more pronounced in developing countries where it is the
second frequent female cancer after breast cancer [1]. In
Gabon, a Sub-Saharan country, cervical cancer is the most
frequent cancer in women [2]. According to data from the
International Agency for Research on Cancer in 2012 [3],
the age-standardized incidence of cervical cancer among
Gabonese woman is 19.9 per 100, 000 women and the
mortality is 8.4 per 100,000.
In the fifteen high risk HPV genotypes, HPV16 and 18
are the two genotypes found in approximately 70 % of
cervical cancer cases worldwide [4]. Thus, the two
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preventive vaccines available (Cervarix® and Gardasil®)
were developed by taking into account the global preva-
lence of these two oncogenic genotypes. However, many
studies on HPV type distribution have shown some geo-
graphical variation [5, 6], suggesting that the usefulness
of these HPV vaccines, in some region of the world, may
be low. Therefore, one of the keys to a successful vaccin-
ation based preventive strategy would be the knowledge
of the distribution of HPV types, both among cervical
cancer cases and in the general population. This infor-
mation is also needed for a virological surveillance of
HPV distribution among the general population before
and after the vaccination.
To date, no study, related to HPV genotypes in cervical
cancers has been conducted in Gabon. Thus, the aim of
the present study was to determine the HPV genotypes
distribution in cervical cancer specimens obtained from
Gabonese women.
Methods
Acquisition of cervical carcinoma specimens
A total of 105 biopsies were investigated. These included
93 Formalin-Fixed Paraffin Embedded (FFPE) tissues
listed between January 2007 and August 2013 at the
Department of Anatomy and Cytology of the University of
Health sciences of Libreville in Gabon and 12 fresh biop-
sies collected from the Cancer Institute of Libreville in
August 2013. The only inclusion criterion was availability
of information on the pathological diagnosis. Histology re-
sults of samples collected showed 92 Squamous Cervical
Carcinoma (SCC) and 13 Adenocarcinoma (ADC).
DNA extraction and quantification
Four sections of 3 μm were cut on a microtome
under strict conditions and deparaffinized with a high-
temperature treatment as described by Steinau et al. [7]
and for the fresh biopsies, two washes with phosphate
buffered saline were done. Then, 200 μL of lysis buffer
(1 M Tris-HCl pH 8, 0.2 M EDTA, 10 % SDS, 5 M NaCl)
containing 10 mg/ml of proteinase K was added to each
tube. The tubes were then incubated at 65 °C overnight.
DNA was isolated using the standard phenol chloroform
method. Then, the DNA was resuspended in nuclease free
water (Bioline, UK) and stored at −20 °C until further use.
After extraction, DNA quantification was performed
through nanodrop 8000 Spectrophotometer (Thermo
Scientific, Wilmington, DE, USA).
HPV detection and genotyping
To evaluate the efficiency of the extraction, integrity of
specimen and absence of PCR inhibitors, all extracted
DNA were subject to an amplification of β-globin
reference gene using the primers pair PCO4/GH20
[8] (Table 1).
HPV detection and typing was carried out by nested
PCR using the L1 consensus primers MY09/11 and
GP5+/6+ [9] (Table 1) and DNA direct sequencing.
The MY and GP+ primers amplified respectively a frag-
ment of 450 and 150 bp. PCR reactions were performed
in a total volume of 25 μl of the reaction mixture con-
taining 10 mM of dNTP, 2.5 mM of Mgcl2, 0.2 U of
GoTaq DNA polymerase, and 10 μM of MY or GP+
primers in 1X Taq polymerase buffer. For the GP+
PCR, 2 μl of the MY PCR products was used as tem-
plate. PCR amplification was performed in a Perkin
Elmer 2400 GeneAmpR® PCR thermal Cycler (Scientific
Support, Inc, Hayward, CA), and was started with an
initial denaturation step (95 °C for 10 min), followed by
40 cycles of 95 °C for 1 min, annealing temperature
(55 °C for MY primers and 48 °C for GP+ primers) for
1 min and 72 °C for 1 min; a final extension of 7 min at
72 °C was performed. For every reaction, ultrapure
water nuclease free (Bioline, UK) was used as a nega-
tive control and DNA of SiHa cell lines was used as
positive control. Amplified PCR products were analyzed
on a 2 % agarose gel stained with Ethidium bromide and
visualized by UV light.
HPV genotyping was performed by DNA sequencing.
The PCR products were purified using the ExoSaP-IT
clean up system (USB, USA) and the sequencing reaction
was performed using GP6+ primer as the sequencing pri-
mer with the BigDye Terminator v3.1 Cycle Sequencing
kit (Applied Biosystems, Foster City, CA, USA) on an ABI
3130 XL DNA analyzer (Applied Biosystems, Foster City,
CA, USA) according to manufacturer’s protocol.
The sequences were analyzed by MEGA software version
6.0.5 (www.megasoftware.net) and results were analyzed
using the BLAST server (http://www.ncbi.nlm.nih.gov/
blast/) available in GenBank database (NCBI, National
Institute of Health, Bethesda, MD, USA). A hypervari-
able region from 34 to 50 bp downstream of the GP5+
binding site was required for identified any HPV
genotype [9]. At least 90 % identities matching be-
tween the query and subject sequences were required
for genotyping [9].
Table 1 Primers used for HPV detection and genotyping




PC04 CAA CTT CAT CCA CGT TCA CC β-globin 268 bp
GH20 GAA GAG CCA AGG ACA GGT AC
MY09 CGT CCM ARR GGA WAC TGA TC L1 450 bp
MY11 GCM CAG GGW CAT AAY AAT GG
GP5+ TTT GTT ACT GTG GTA GAT ACT AC L1 142 bp
GP6+ GAA AAA TAA ACT GTA AAT CAT ATT C
M = A + C, R = A + G, W = A + T, Y = C + T
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Results
HPV DNA prevalence
Amplification of the housekeeping gene (β-globin) with
PCO4/GH20 primers was successful for 91.4 % (96/105)
cervical cancer samples (9 FFPE and 1 fresh biopsy) and
therefore were eligible for the further analyses. HPV
DNA was detected in all the 96 cervical cancer samples
positive for β-globin detection. According to the histo-
pathological distribution, HPV detection showed that
90.2 % (83/92) of SCC cases and the entire ADC cases
were positive for HPV DNA (Table 2).
HPV genotype prevalence and distribution
Analysis of sequencing results showed that 4 oncogenic
HPV genotypes: 16, 18, 33 and 31, and one possibly carci-
nogenetic genotype, HPV 70 were present in the cervical
cancer specimens studied. HPV 16 was the most prevalent
genotype representing 58.3 % [95 % IC: 48.44–68.16] of
HPV positive cases followed by HPV 33 [25.0 %; 95 % IC:
16.34–33.66], HPV 18 [8.4 %; 95 % IC: 2.86–13.94],
HPV 70 [7.3 %; 95 % IC: 2.1–12.5] and HPV 31
[1.1 %; 95 % IC: −0.986–3.186]. In SCC and ADC cases,
the prevalence of HPV 16 was 56.6 % (47/83) and 69.2 %
(9/13) respectively. HPV 18 was detected in 7.7 % (1/13)
of ADC and in 8.4 % (7/83) of SCC cases. All the HPV 70
cases found in this study were SCC (Table 1).
Discussion
In the WHO middle African countries, data about
HPV distribution in relation to cervical abnormalities
are still lacking. This work is the first comprehensive
study conducted in Gabon that investigated the distri-
bution of HPV genotypes in invasive cervical cancer.
In Gabon, as reported in a study from Congo-Brazzaville
[10], a neighbouring country, the number of pathological
laboratories are really limited. Furthermore, the specimens
used in this study were obtained from women who
came from different regions of the country and
represents a wide social and economic strata. There-
fore, the results of this study could reflect the trend
distribution of oncogenic HPV among cervical cancer
cases in our country.
Worldwide HPV prevalence in cervical carcinomas is
reported to be 99.7 % and cases of cervical cancer with-
out HPV is extremely rare [11]. Of the 96 cervical can-
cer specimens genotyped, all were determined as
positive for HPV DNA. This high HPV prevalence found
corroborate with an international study conducted by
Sanjose S et al. [12] that used FFPE tissues collected
from the five continents with slight differences depend-
ing on the region. Some others African studies reported
a high HPV prevalence. In a Sudanese and Ethiopian
study, [13] the HPV prevalence was respectively 94 and
93.1 % of cervical carcinoma cases. In a sub-Saharan
study [14] conducted with cervical samples from
Ghana, South Africa and Nigeria, the HPV prevalence
was 93.9; 92.1; and 84.9 % respectively. Another study
conducted in Ghana [15] reported a high prevalence of
98 % in cervical cancer cases.
Correlation between histological status and HPV geno-
types has been observed in several studies. SCC was
most likely associated with HPV 16 whereas HPV 18
was most common in ADC [16–18]. However, in our
study, HPV 16 was the most prevalent in all histological
categories of cervical cancer cases. Indeed, this HPV
genotype was found in 69.2 % of ADC and in 58.3 % of
SCC. However, HPV 18 was found in only one case
(7.7 %) of ADC and in 8 cases (8.3 %) of SCC. Our
results suggest that HPV 16 remains prevalent whatever
the histological type in our population of cervical cancer
cases and highlight the oncogenic potential of this
genotype.
In our study, we found 4 of these oncogenic geno-
types. HPV 16 was the most predominant type in all
HPV positives samples representing 58.3 % of cases
followed by HPV 33 (25 %). The findings of this
Table 2 Distribution of HPV genotypes by histopathological categories
Type of malignant lesions
All samples (n = 96) 95 % IC ADC (n = 13) 95 % IC SCC (n = 83) 95 % IC
HRa HPV+ 89 (92.7) 13 (100) 76 (91.6)
Pcb HPV+ 7 (7.3) 0 (0.0) 7 (8.4)
HR genotypes
HPV 16 56 (58.3) 48.4–68.2 9 (69.2) 44.1–94.3 47 (56.6) 45.9–67.3
HPV 33 24 (25.0) 16.3–33.7 3 (23.1) 0.2–46 21 (25.3) 15.9–34.7
HPV 18 8 (8.3) 2. 9–13.9 1 (7.7) −6.8–22.2 7 (8.4) 2.4–14.4
HPV 31 1 (1.1) −0.9–3.1 0 (0.0) – 1 (1.2) −1.1–3.5
Pcb genotypes
HPV 70 7 (7.3) 2.1–12.5 0 (0.0) – 7 (8.4) 2.4–14.4
Percentage is in bracket. aHigh Risk. bPossibly carcinogenetic
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study confirms the fact that there is a geographical
variations in the genotype specific HPV distribution
globally [19]. The distribution determined in this study
was similar to those reported in some African studies
[10, 20, 21], while for others African countries the dis-
tribution was different [5, 13, 14].
In a recent upgraded IARC systemic review about hu-
man carcinogens [22], HPV 70 earlier considered as a
low-risk HPV genotype has been considered as a pos-
sibly carcinogenetic genotype. In our study, this HPV
genotype was found in 7.4 % of the cervical cancer sam-
ples. This genotypes was found in cervical cancer cases
in several studies [14, 23–26]. Our findings highlight the
fact that an epidemiological surveillance would be neces-
sary for this uncommonly genotype in our population.
The HPV genotypes distribution found in this study
differ from those of the preliminary study among
Gabonese women of childbearing age, regardless of their
cervical cytology [27]. In fact, the oncogenic genotypes
53, 58 and 16 were found to be the most prevalent in
decreasing order. Moreover, HPV 70 was also found in
6 % of HPV positives cases. The absence of the onco-
genic genotype 53 and 58 in our study suggest that they
may be less commonly associated with cervical cancer in
our population.
This study also has a limitation. These specimens
could very probably harbor multiple infections and
therefore could not be typed by DNA sequencing. DNA
sequencing technique has been facing limitation when
the specimen harbors multiple genotypes. Other geno-
typing approach would be used to determine the mul-
tiple HPV types in our future studies.
At last, from a prevention point of view, our study
suggests that the introduction of HPV vaccination may
reduce the burden of cervical cancer in Gabon and
economic efforts in the treatment of this preventable
disease.
Conclusion
This study provides the first information about the HPV
distribution in cervical cancer cases in Gabonese women.
Our study showed that HPV 16, 33 and 18 were the most
common genotypes in women with SCC and ADC.
The determination of HPV distribution is important
for implementing programs of vaccination and virological
surveillance. Our findings highlight that the introduction
of HPV vaccination in Gabon should be considered
and will offer a significant opportunity for the Gabonese
National Health Program to control cervical cancer
disease and save women lives.
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